Bone mineral density in adult patients with major thalassaemia: Our experience and a brief review of the literature

Endokrynologia Polska

Volumn 63, Issue 4, 2012, Pages 264-269

  Izadyar, Sina ^a   Fazeli, Mohammadali ^a   Izadyar, Mina ^a   Salamati, Peyman ^b   Gholamrezanezhad, Ali ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone mineral density; Osteopenia; Osteoporosis; Thalassaemia

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; DEFEROXAMINE; IRON CHELATING AGENT; PHOSPHORUS; VITAMIN D;

ADOLESCENT; ADULT; AGE; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; BONE DENSITY; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; DISEASE DURATION; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON CHELATION; LUMBAR SPINE; MALE; MEDICAL HISTORY; OSTEOPENIA; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; PREDICTIVE VALUE; PREVALENCE; THALASSEMIA MAJOR;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; BETA-THALASSEMIA; BONE DENSITY; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPOGONADISM; HYPOTHYROIDISM; IRAN; MALE; OSTEOPOROSIS; PREVALENCE; RISK FACTORS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84865976707     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hamed EA, Mohamed NA, El-Metwally TH, Kamal MM. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappa beta ligand systems, and bone mineral density. J Pediatr Hematol Oncol 2010; 32: 267-273.
2. Chapelon E, Garabedian M, Brousse V, Souberbielle JC, Bresson JL, de Montalembert M. Osteopenia and vitamin D deficiency in children with sickle cell disease. Eur J Haematol 2009; 83: 572-578.
3. Dundar U, Kupesiz A, Ozdem S et al. Bone metabolism and mineral density in patients with beta thalassemia major. Saudi Med J 2007; 28: 1425-1429.
4. Pietrapertosa AC, Minenna G, Colella SM, Santeramo TM, Renni R, D'Amore M. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major. Panminerva Med 2009; 51: 17-23.
5. Voskaridou E, Terpos E. Pathogenesis and management of osteoporosis in thalassemia. Pediatr Endocrinol Rev 2008; 6 (Suppl 1): 86-93.
6. Scacchi M, Danesi L, Cattaneo A et al. Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites. Clin Endocrinol (Oxf) 2008; 69: 202-207. (Pubitemid 352009023)
7. Mahachoklertwattana P, Pootrakul P, Chuansumrit A et al. Association between bone mineral density and erythropoiesis in Thai children and adolescents with thalassemia syndromes. J Bone Miner Metab 2006; 24: 146-152.
8. Bielinski BK, Darbyshire PJ, Mathers L et al. Impact of disordered puberty on bone density in beta thalassaemia major. Br J Haematol 2003; 120: 353-358. (Pubitemid 36194189)
9. Bisbocci D, Livorno P, Modina P et al. Osteodystrophy in thalassemia major. Ann Ital Med Int 1993; 8: 224-226. (Pubitemid 24063768)
10. Skordis N, Ioannou YS, Kyriakou A et al. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major. Pediatr Endocrinol Rev 2008; 6 (Suppl 1): 144-148.
11. Vogiatzi MG, Macklin EA, Fung EB et al.; Thalassemia Clinical Research Network. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 2009; 24: 543-557.
12. Gaudio A, Morabito N, Xourafa A et al. Bisphosphonates in the treatment of thalassemia associated osteoporosis. J Endocrinol Invest 2008; 31: 181-184. (Pubitemid 351596981)
13. Vogiatzi MG, Autio KA, Mait JE, Schneider R, Lesser M, Giardina PJ. Low bone mineral density in adolescents with beta-thalassemia. Ann NY Acad Sci 2005; 1054: 462-466. (Pubitemid 43031057)
14. Kyriakou A, Savva SC, Savvides I et al. Gender differences in the prevalence and severity of bone disease in thalassaemia. Pediatr Endocrinol Rev. 2008; 6 (Suppl 1): 116-122.
15. El-Edel RH, Ghonaim MM, Abo-Salem OM, El-Nemr FM. Bone mineral density and vitamin D receptor polymorphism in beta-thalassemia major. Pak J Pharm Sci 2010; 23: 89-96.
16. Leung TF, Chu Y, Lee V et al. Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits. Hemoglobin. 2009; 33: 361-369.
17. Shamshirsaz AA, Bekheirnia MR, Kamgar M et al. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocr Disord 2003; 3: 4.
18. Orvieto R, Leichter I, Rachmilewitz EA, Margulies JY. Bone density, mineral content, and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine. Calcif Tissue Int 1992; 50: 397-399.
19. D'Eufemia P, Finocchiaro R, Celli M et al. Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate. Biomed Pharmacother 2010; 64: 271-274.
20. Mylona M, Leotsinides M, Alexandrides T, Zoumbos N, Dimopoulos PA. Comparison of DXA, QCT and trabecular structure in beta thalassaemia. Eur J Haematol 2005; 74: 430-437. (Pubitemid 40545569)
21. Vogiatzi MG, Autio KA, Schneider R, Giardina PJ. Low bone mass in prepubertal children with thalassemia major: insights into the pathogenesis of low bone mass in thalassemia. J Pediatr Endocrinol Metab 2004; 17: 1415-1421. (Pubitemid 39433517)
22. Pafumi C, Roccasalva L, Pernicone G et al. Osteopenia in female beta-thalassemic patients. J Pediatr Endocrinol Metab 1998; 11 (Suppl 3): 989-991.
23. Lala R, Chiabotto P, Di Stefano M, Isaia GC, Garofalo F, Piga A. Bone density and metabolism in thalassaemia. J Pediatr Endocrinol Metab 1998; 11 (Suppl 3): 785-790. (Pubitemid 29065854)
24. Di Matteo R, Liuzza F, Manicone PF et al. Bone and maxillofacial abnormalities in thalassemia: a review of the literature. J Biol Regul Homeost Agents 2008; 22: 211-216.
25. Doxiadis S, Georgaki E, Papamichael D, Papadakou-Lagogianni S, Lapatsanis P. Bone density in thalassemic children during the course of the disease. Pediatr Res 1978; 12: 811-815. (Pubitemid 8375433)
26. Jensen CE, Tuck SM, Agnew JE et al. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998; 103: 911-915. (Pubitemid 29012624)
27. Fung EB, Xu Y, Kwiatkowski JL et al. Thalassemia Clinical Research Network. Relationship between Chronic Transfusion Therapy and Body Composition in Subjects with Thalassemia. J Pediatr 2010; 157: 641-647.
28. Tantawy AA, El Kholy M, Moustafa T, Elsedfy HH. Bone mineral density and calcium metabolism in adolescents with beta-thalassemia major. Pediatr Endocrinol Rev 2008; 6 (Suppl 1): 132-135.
29. Shamshirsaz AA, Bekheirnia MR, Kamgar M et al. Bone mineral density in Iranian adolescents and young adults with beta-thalassemia major. Pediatr Hematol Oncol 2007; 24: 469-479. (Pubitemid 47360014)
30. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int. 2001; 12: 570-575. (Pubitemid 32777434)
31. Karimi M, Ghiam AF, Hashemi A, Alinejad S, Soweid M, Kashef S. Bone mineral density in beta thalassemia major and intermedia. Indian Pediatr 2007; 44: 29-32. (Pubitemid 46168872)
32. Tiosano D, Hochberg Z. Endocrine complications of thalassemia. J Endocrinol Invest 2001; 24: 716-723. (Pubitemid 32982341)
33. Christoforidis A, Kazantzidou E, Tsatra I et al. Normal lumbar bone mineral density in optimally treated children and young adolescents with beta-thalassaemia major. Hormones (Athens) 2007; 6: 334-340.
34. Skordis N, Michaelidou M, Savva SC et al. The impact of genotype on endocrine complications in thalassaemia major. Eur J Haematol 2006; 77: 150-156.
35. Sowińska-Przepiera E, Andrysiak-Mamos E, Jarza̧bek-Bielecka G, Friebe Z, Syrenicz A. Effects of oestrogen deficiency on bone mine- ralisation in girls during "adolescent crisis". Endokrynol Pol 2011; 62: 538-546.
36. Sowińska-Przepiera E, Andrysiak-Mamos E, Syrenicz J, Jarza̧bek-Bielecka G, Friebe Z, Syrenicz A. Polymorphism of the vitamin D3 receptor gene and bone mineral density in girls with functional hypothalamic amenorrhea subjected to oestroprogestagen treatment. Endokrynol Pol 2011; 62: 492-498.
37. Horst-Sikorska W, Wawrzyniak A. The role of hormonal therapy in osteoporosis. Endokrynol Pol 2011; 62: 61-64.
38. Carmina E, Di Fede G, Napoli N et al. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int 2004; 74: 68-71. (Pubitemid 38166607)
39. Molyvda-Athanasopoulou E, Sioundas A, Karatzas N, Aggellaki M, Pazaitou K, Vainas I. Bone mineral density of patients with thalassemia major: four-year follow-up. Calcif Tissue Int 1999; 64: 481-484. (Pubitemid 29244790)
40. Skordis N, Efstathiou E, Kyriakou A, Toumba M. Hormonal dysregulation and bones in thalassaemia - an overview. Pediatr Endocrinol Rev. 2008; 6 (Suppl 1): 107-115.